Indian Markets Poised for Resilience Amid US Tariffs, Expert Suggests
Sunil Subramaniam expects Indian markets to consolidate rather than sharply correct as US tariffs take effect on August 27. FII flows may remain subdued due to high valuations and trade uncertainties, but domestic investors are expected to support the market through sectoral rotation. Capital goods sector shows promise with private capex nearing 80% utilization. Auto sector anticipates strong festive demand, while pharmaceuticals present a mixed outlook. US drug price cuts could benefit Indian contract manufacturers.

*this image is generated using AI for illustrative purposes only.
Market expert Sunil Subramaniam has offered insights on the Indian markets' outlook in light of impending US tariffs on Indian goods. According to Subramaniam, the markets are well-prepared for the tariffs set to take effect on August 27, with investors having already factored this development into their strategies.
Market Consolidation Expected
Subramaniam anticipates a period of consolidation for Indian markets rather than sharp corrections. This stability is expected despite the implementation of US tariffs, which he believes have been largely priced in by market participants.
Foreign and Domestic Investment Dynamics
The expert points out that foreign institutional investor (FII) flows are likely to remain subdued. Two key factors contribute to this outlook:
- High valuations in the Indian market
- Ongoing trade uncertainties
However, Subramaniam expects domestic investors to continue providing support to the market through a strategy of sectoral rotation.
Sectoral Opportunities
Capital Goods Sector
Subramaniam highlights promising opportunities in the capital goods sector, driven by robust domestic demand. He notes that private capital expenditure (capex) is showing encouraging signs, with capacity utilization approaching 80%.
Automotive Sector
The auto sector is poised for strong festive demand across various segments:
- Two-wheelers
- Entry-level cars
- Tractors
- Commercial vehicles
However, Subramaniam cautions that export-oriented components within the automotive industry may face some pressure.
Pharmaceutical Sector
The pharmaceutical sector presents a mixed outlook:
- Strong domestic growth prospects
- Potential concerns related to tariffs
Interestingly, Subramaniam suggests that US drug price cuts could potentially benefit Indian contract manufacturers through increased outsourcing.
Conclusion
Despite the looming US tariffs, Subramaniam's analysis paints a picture of resilience for Indian markets. The expert's insights suggest that while certain sectors may face challenges, others are well-positioned to capitalize on domestic demand and potential global shifts in manufacturing and outsourcing practices.
Investors and market participants will likely be watching closely to see how these predictions play out in the coming months, particularly as the festive season approaches and the impact of the new tariffs begins to materialize.